# Pegasys in Patients With Chronic Myeloid Leukemia (CML)

> **NCT01392170** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 2 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** PEG-IFNá-2a

## Key facts

- **NCT ID:** NCT01392170
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-10
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Slow Accrual
- **Last updated:** 2015-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01392170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01392170, "Pegasys in Patients With Chronic Myeloid Leukemia (CML)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01392170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*